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ABSTRACT
Friedreich’s ataxia (FRDA) is an autosomal recessive
neurodegenerative disorder caused by a GAA repeat expansion
mutation within intron 1 of the FXN gene, resulting in reduced levels
of frataxin protein. We have previously reported the generation of
human FXN yeast artificial chromosome (YAC) transgenic FRDA
mouse models containing 90-190 GAA repeats, but the presence of
multiple GAA repeats within these mice is considered suboptimal.
We now describe the cellular, molecular and behavioural
characterisation of a newly developed YAC transgenic FRDA
mouse model, designated YG8sR, which we have shown by DNA
sequencing to contain a single pure GAA repeat expansion. The
founder YG8sR mouse contained 120 GAA repeats but, due to
intergenerational expansion, we have now established a colony of
YG8sR mice that contain ~200 GAA repeats. We show that YG8sR
mice have a single copy of the FXN transgene, which is integrated
at a single site as confirmed by fluorescence in situ hybridisation
(FISH) analysis of metaphase and interphase chromosomes. We
have identified significant behavioural deficits, together with a
degree of glucose intolerance and insulin hypersensitivity, in YG8sR
FRDA mice compared with control Y47R and wild-type (WT) mice.
We have also detected increased somatic GAA repeat instability in
the brain and cerebellum of YG8sR mice, together with significantly
reduced expression of FXN, FAST-1 and frataxin, and reduced
aconitase activity, compared with Y47R mice. Furthermore, we
have confirmed the presence of pathological vacuoles within
neurons of the dorsal root ganglia (DRG) of YG8sR mice. These
novel GAA-repeat-expansion-based YAC transgenic FRDA mice,
which exhibit progressive FRDA-like pathology, represent an
excellent model for the investigation of FRDA disease mechanisms
and therapy.
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INTRODUCTION
Friedreich’s ataxia (FRDA) is an autosomal recessive disorder,
characterised by progressive neurodegeneration, cardiomyopathy,
diabetes mellitus and skeletal deformities (Pandolfo, 2009). It is
primarily caused by a GAA repeat expansion mutation within intron
1 of the FXN gene, resulting in reduced levels of frataxin protein
(Campuzano et al., 1997; Campuzano et al., 1996). Unaffected
individuals have 5 to 40 GAA repeat sequences, whereas affected
individuals have ~70 to more than 1000 GAA triplets (Pandolfo,
2002). Frataxin is a mitochondrial protein involved in iron-sulphur
cluster and heme biosynthesis (Gerber et al., 2003). Reduction in
frataxin expression leads to oxidative stress, mitochondrial iron
accumulation and consequential cell death, with the primary sites
being large sensory neurons of the dorsal root ganglia (DRG) and
the dentate nucleus of the cerebellum (Campuzano et al., 1997;
Koeppen, 2011). Although FRDA is the most common inherited
ataxia, affecting 1 in 50,000 Caucasians, there is currently no
effective treatment. Therefore, to investigate FRDA molecular
disease mechanisms and therapy, a number of different FRDA cell
and mouse models have been developed (Perdomini et al., 2013).
Our lab have previously established three human FXN YAC
transgenic mouse models that express human FXN in a mouse-Fxn-
null background: Y47R, containing normal-sized (GAA)9 repeats,
and YG8R and YG22R, which initially contained expanded GAA
repeats of 90-190 units and 190 units, respectively, but which have
subsequently been bred to contain expanded GAA repeats of 120-
220 units and 170-260 units, respectively (Al-Mahdawi et al., 2004;
Al-Mahdawi et al., 2006; Anjomani Virmouni et al., 2014; Pook et
al., 2001). We have demonstrated that both YG8R and YG22R
FRDA mice express comparatively decreased levels of human FXN
mRNA and frataxin protein in comparison to wild-type (WT) or
Y47R control mice (Al-Mahdawi et al., 2008; Al-Mahdawi et al.,
2006; Anjomani Virmouni et al., 2014). Furthermore, both YG8R
and YG22R mice exhibit a progressive FRDA-like molecular
disease phenotype, which includes intergenerational and somatic
instability of the GAA repeat expansion mutation (Al-Mahdawi et
al., 2004; Clark et al., 2007), as well as mild progressive behavioural
motor coordination deficits, compared with WT or Y47R controls,
that are consistent with FRDA disease (Al-Mahdawi et al., 2006;
Anjomani Virmouni et al., 2014). In this study, we report the
generation of a new line of GAA-repeat-expansion-based FRDA
mice derived from YG8R breeding, designated YG8sR, which
contains a single copy of the FXN transgene and a single pure GAA
repeat expansion mutation, which was 120 GAA repeats in size in
the founder mouse. The GAA repeat remains as a single unit upon
transmission, but exhibits both intergenerational and somatic
variability in repeat size. We demonstrate progressive behavioural
deficits in YG8sR mice, together with significant decreases of FXN
and FAST-1 transcripts and frataxin protein expression compared
with C57BL6/J (B6) WT and Y47R controls. In addition, the
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YG8sR mice exhibited pathology of the DRG, revealed by the
presence of numerous vacuoles within the large sensory neuronal
cell bodies, together with reduced levels of brain aconitase activity,
in line with an FRDA-like phenotype. Therefore, these YG8sR mice
currently represent the most suitable GAA-repeat-based YAC
transgenic mouse model to investigate potential FRDA therapies.
These mice are available from The Jackson Laboratory: YG8sR
(#024113).
RESULTS
Identification of YG8sR mice with an FXN transgene
containing a single pure GAA repeat sequence 
During normal breeding of previously characterised YG8R FXN
YAC transgenic mice, which contain multiple GAA repeats (Al-
Mahdawi et al., 2004; Al-Mahdawi et al., 2006), we serendipitously
identified a unique founder mouse that contained a single GAA
repeat sequence of 120 units (supplementary material Fig. S1). The
YAC transgene has previously been shown by gene scanning at The
Jackson Laboratory to be integrated into mouse chromosome 16 (C.
Lutz, The Jackson Laboratory, personal communication). From this
founder mouse, we established a new line of GAA-repeat-expansion-
containing FXN YAC transgenic mice on a predominantly C57BL6/J
background, designated YG8sR. We observed that the GAA repeat
was transmitted from parent to offspring as a single discrete entity,
but with variation of the specific GAA repeat size. Therefore, by
selecting for intergenerational GAA repeat expansion events, we have
been able to establish a colony of YG8sR mice that now contain
GAA repeats of ~200 units (supplementary material Fig. S1). The
single GAA repeat was shown to be a pure GAA repeat, firstly by
MboII digestion (Holloway et al., 2011) and then by DNA
sequencing analysis (supplementary material Fig. S2). The FXN
transgene copy number was then investigated in YG8sR mouse
genomic DNA samples using TaqMan real-time PCR. The results
indicated that YG8sR mice had a single copy of the FXN transgene
(Fig. 1A). In addition, to determine the integration site of the
transgenic FXN gene and to confirm the TaqMan copy-number
results, fluorescence in situ hybridisation (FISH) using dual-colour
probes containing overlapping bacterial artificial chromosome (BAC;
RP11-265B8 and RP11-876N18) sequences was performed on both
metaphase and interphase spreads of YG8sR cultured fibroblast cells.
The YG8sR cells showed one hybridisation signal, indicating the
presence of a single integration site containing one copy of the FXN
transgene (Fig. 1B).
YG8sR mice exhibit behavioural deficits
The motor coordination ability of YG8sR FRDA mice was assessed
on a rotarod treadmill at monthly time points from 4-12 months of
age, using B6 and Y47R mice as controls. Ten mice were assessed
for each group, five males and five females. As shown in Fig. 2, the
coordination ability of the YG8sR mice was significantly reduced
when compared with B6 and Y47R controls. This trend held true
when both male and female values were taken together (Fig. 2A) or
when male and female values were considered alone (Fig. 2B,C).
However, no significant difference was detected in the rotarod
performance of YG8sR males compared with Y47R controls. This
might be due to the higher body weight of Y47R control mice,
affecting their rotarod performance (Fig. 2D-F). YG8sR mice were
lighter than Y47R controls, but heavier than B6 controls, when both
male and female values were taken together (Fig. 2D) or when male
values were considered alone (Fig. 2E), but there was no statistically
significant difference between YG8sR and B6 females (Fig. 2F).
Locomotor activity tests were performed over a 2-minute period
and repeated four times for each mouse using an open-field beam-
breaker activity monitor. Ten mice (five males and five females)
were assessed monthly for each group from 4-12 months of age.
YG8sR mice exhibited significantly reduced average velocity (total
distance covered divided by the total time elapsed) compared with
B6 and Y47R controls, whether male and female values were taken
together or analysed separately (Fig. 3A-C). The ambulatory
distance (total distance covered by the mice within a specific time)
of YG8sR FRDA mice was significantly less than the controls when
male and female values were taken together or when males were
analysed separately, but higher ambulatory values were observed in
YG8sR females (supplementary material Fig. S3 and Table S1).
Significant decreases in the vertical count and vertical time (total
events and duration of the mouse standing on hind legs) were
detected in the YG8sR mice compared with the controls when
analysing males and females together and separately (supplementary
material Fig. S4 and Table S1). Significant decreases in jump count
and jump time were also detected in the YG8sR mice compared
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TRANSLATIONAL IMPACT
Clinical issue
Friedreich’s ataxia (FRDA) is an inherited neurodegenerative disorder
that also affects the heart and pancreas. It is the most common
hereditary ataxia, affecting approximately 1 in 50,000 individuals in the
Caucasian population. It is caused by a GAA repeat expansion mutation
within intron 1 of the FXN gene, which results in decreased expression
of frataxin, the essential mitochondrial protein that this gene encodes. At
present, there is no therapy for FRDA; therefore, much research effort is
currently focused on the development of optimal cell and animal models
of FRDA for preclinical therapeutic testing. The YG8R mouse model of
FRDA – FXN-knockout mice that are also hemizygous for the YG8
transgene (which carries two tandem copies of the human FXN gene
with two GAA trinucleotide repeat expansions) – has been used to
successfully test the safety and efficacy of frataxin-increasing drug
compounds, such as histone deacetylase inhibitors and interferon-γ.
However, it is not an optimal model because it contains multiple GAA
repeat stretches, does not express particularly low levels of frataxin and
has a very mild overall phenotype, which is not conducive to effective
preclinical testing. 
Results
Here, the authors report on the development and characterisation of a
novel FRDA mouse model from YG8R breeding, designated YG8sR.
PCR genotyping analysis and DNA sequencing showed that YG8sR
mice contain a single GAA repeat expansion mutation, and that this
expansion has both intergenerational and somatic instability, as is
detected in humans with FRDA. These mice also have significantly
decreased levels of frataxin expression in all tissues tested and show
FRDA-like phenotypes such as defects in coordination behaviour,
reduced brain aconitase enzyme activity and pathological dorsal root
ganglia histology.
Implications and future directions
These novel YG8sR GAA-repeat-expansion-based human FXN
transgenic mice represent an excellent model for the investigation of
FRDA disease mechanisms and therapy, adding to and optimising the
currently available models for this neurodegenerative disease. YG8sR
mice will be particularly useful for any FRDA therapeutic strategies using
compounds that target the mutated human FXN gene sequence to
increase frataxin expression, such as DNA or RNA oligotherapies.
Additionally, to assist future FRDA therapeutic preclinical studies, the
authors aim to continue selectively breeding YG8sR mice to produce
ever larger GAA repeat expansions that cause further reductions in
frataxin expression. Other laboratories are also making efforts to
generate similar human FXN BAC transgenic mice with very large pure
GAA repeats. Future studies using the YG8sR, and subsequent, models

















with the controls when analysing males and females together or
males separately, but the female-only values showed no statistically
significant difference to controls (supplementary material Fig. S5
and Table S1).
Beam-walk performance testing was used to assess the
coordination ability of 12-month-old YG8sR FRDA mice compared
with B6 and Y47R controls. Ten mice (five males and five females)
were assessed for each group and the average latency of four trials
on beams of 22-mm and 12-mm diameter was recorded. As evident
in Fig. 3D-F, YG8sR mice took significantly longer to cross either
the 22-mm or the 12-mm beam compared with the controls when
analysing males and females together and separately, although no
significant difference was detected in the beam-walk performance
of YG8sR males on the 12-mm beam compared with Y47R
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Fig. 1. Transgene copy number. (A) Two TaqMan copy-number assays were applied: Hs05092416-cn assay (ATX 416; represented in black) was designed to
amplify a 106-bp fragment of FXN within intron 3, and Hs02407730-cn assay (ATX 730; represented in grey) was designed to amplify an 80-bp fragment of
FXN within intron 1 and exon 2. Human mammary epithelial cell (HMEC) with copy numbers of two served as a calibrator. Error bars=s.d. n=2.
(B) Determination of the integration site of the transgenic FXN gene by FISH. Biotin-labelled RP11-265B8 and digoxigenin-labelled RP11-876N18 probes were
hybridised onto interphase and metaphase chromosomes (DAPI stained) of YG8sR cells. YG8sR showed one hybridisation signal, indicating a single
integration site of the FXN transgene containing one copy of the FXN gene. Scale bars: 10 μm.
Fig. 2. Rotarod and weight analysis. YG8sR FRDA mice show a coordination deficit compared with B6 and Y47R controls when (A) both male and female
values are taken together (n=10 mice per genotype), or when results are for (B) males alone (n=5 mice per genotype) or (C) females alone (n=5 mice per
genotype). (D) Weight analysis of YG8sR compared with B6 and Y47R controls when both male and female values were taken together (n=10 mice per
genotype). The results indicated a significant increase in weight of YG8sR FRDA mice in comparison to B6 control. A similar tendency was seen when (E) male
















controls. This might be due to the higher body weight of Y47R male
mice (Fig. 2E), affecting their balance and performance on the
narrower beam.
Groups of ten (five male and five female) 12-month-old mice
were assessed for their ability to hang on to a horizontal wire by
their forepaws. YG8sR mice fell off the wire quicker when
compared with Y47R and B6 controls, suggesting a reduced overall
forelimb strength (Fig. 4A-C). Statistically significant differences
were obtained for all comparisons, with the exception of YG8sR
males versus Y47R control male mice, which might be due to the
Y47R male mice being heavier than YG8sR males (Fig. 2E), so
having a reduced ability to hang on to the wire for any extended
period of time. To further assess forelimb grip strength, a grip
strength meter was used to measure the peak force with which mice
pulled a wire. Ten 12-month-old mice were assessed for each group
(five males and five females). The results showed statistically
significant decreases in grip strength of YG8sR mice compared with
both Y47R and B6 controls, whether both male and female values
were taken together or when male and female values were
considered alone (Fig. 4D-F).
Gait abnormalities were assessed by monitoring the footprint
patterns of 12-month-old mice after they had walked along a narrow
gangway. Analysis of the footprints indicated statistically significant
decreases in both stride length and base width of YG8sR mice
compared with Y47R and B6 controls, whether both male and
female values were taken together or when male and female values
were considered alone (supplementary material Fig. S6).
YG8sR mice exhibit glucose intolerance
A fasting glucose-tolerance test was performed on groups of ten
(five male and five female) 12-month-old mice, revealing higher
blood glucose concentrations in YG8sR mice compared with Y47R
and B6 controls, indicating a degree of glucose intolerance in
YG8sR mice (Fig. 5A-C). This effect was more pronounced in
males compared to females. Subsequent insulin-tolerance testing
showed that YG8sR mice had enhanced glucose utilisation after
insulin injection compared with controls, suggesting insulin
hypersensitivity (Fig. 5D-F).
YG8sR mice exhibit somatic GAA-repeat instability together
with reduced FXN, frataxin and FAST-1 expression in YG8sR
tissues
Somatic GAA-repeat instability was assessed by PCR analysis of
genomic DNA from a variety of tissues from 12-month-old YG8sR
mice. Our analysis revealed tissue-selective GAA repeat expansions,
ranging from ~120 to 150 repeats, in the brain, cerebellum and liver
tissues, but most prominently in the brain and cerebellum
(supplementary material Fig. S7). To assess the effect of the GAA
repeat expansion on FXN mRNA expression in the YG8sR FRDA
mice, qRT-PCR measurements were performed using primers
designed to detect both human and mouse FXN cDNA. Analysis of
the YG8sR mice (both male and female) revealed a very significant
reduction of FXN mRNA in the brain (22%, P<0.001), cerebellum
(18%, P<0.001) and liver (17%, P<0.001) tissues compared with
Y47R control mice, which have previously been shown to contain
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Fig. 3. Average velocity and beam-walk analysis of YG8sR FRDA mice. (A-C) Average velocity. (A) YG8sR displayed significantly decreased average
velocity compared with B6 and Y47R controls when both male and female values were taken together (n=10 mice per genotype). Analysis of (B) males and (C)
females separately (n=5 mice per genotype). (D-F) Beam walk. (D) Analysis of YG8sR compared to B6 and Y47R controls showed a coordination deficit on
both 22-mm and 12-mm beams (n=10 mice per genotype) when both male and female values were taken together. Analysis of (E) males and (F) females
separately (n=5 mice per genotype). Values represent mean±s.e.m. *P<0.05, **P<0.01 and ***P<0.001. Statistical differences between YG8sR FRDA and B6
















one copy of the human transgene and relatively high FXN
expression of unknown cause compared with B6 mice (Anjomani
Virmouni et al., 2014) (Fig. 6A). In addition, The FXN mRNA
expression levels were also decreased to 47% (P<0.001) in the liver
and 55% (P<0.001) in the cerebellum of the YG8sR compared with
the B6 control (Fig. 6A). On the other hand, analysis of the male
YG8sR mice revealed reduced FXN mRNA levels of 20% (P<0.01)
and 85% (P=0.3) in the brain, 16% (P<0.01) and 56% (P=0.09) in
the cerebellum, and 21% (P=0.08) and 57% (P=0.1) in the liver
compared with Y47R and B6 controls, respectively (Fig. 6B).
Furthermore, the levels of transgenic FXN mRNA expression in
YG8sR females were decreased to 25% (P<0.01) in the brain, 21%
(P<0.01) in the cerebellum and 14% (P<0.05) in the liver tissues
(Fig. 6C). The FXN expression levels were also decreased in
cerebellum (53%, P<0.05) and liver (38%, P<0.05) of YG8sR
females compared with endogenous B6 Fxn mRNA (Fig. 6C). To
determine the levels of human frataxin expression in the YG8sR
FRDA mouse model, frataxin protein expression levels were
measured by lateral flow immunoassay with the Frataxin Protein
Quantity Dipstick assay kit. Analysis of YG8sR males and females
together revealed that frataxin expression was significantly
decreased to ~16% (P<0.001) in the brain, 70% (P<0.001) in the
cerebellum and 24% (P<0.001) in the liver tissues compared with
Y47R controls (Fig. 6D). Males and females were also analysed
separately in order to determine the gender-specific differences in
the FXN expression level. The results from the males revealed a
significant decrease of FXN expression in the brain (14%, P<0.001),
and also in the liver (22%, P<0.001) of YG8sR mice (Fig. 6E). The
same trend was also observed in the cerebellum of YG8sR males
(69%, P=0.08); however, the differences did not reach a statistical
significance (Fig. 6E). Analysis of the females showed a marked
reduction of FXN expression in the brain (17%, P<0.001),
cerebellum (72%, P<0.05) and liver (25%, P<0.001) of YG8sR
female mice (Fig. 6F). However, because this approach uses a
human-specific anti-frataxin antibody, it did not allow comparison
of the human frataxin levels in the YG8sR FRDA transgenic mice
with B6 mouse frataxin levels. Levels of the human-specific frataxin
antisense transcript, FAST-1, were also measured by qRT-PCR and
were found to be significantly decreased in YG8sR mouse tissues
compared with Y47R controls (Fig. 7A).
YG8sR mice show decreased aconitase activity and DRG
histopathology
Aconitase enzyme activities were measured in the YG8sR and
Y47R control brain tissue total cell lysates. Our results showed
significantly decreased aconitase activity in the YG8sR brain tissue
(76%, P<0.05) compared with in Y47R controls (Fig. 7B).
Hematoxylin and eosin (H&E) staining of DRG from 12-month-old
mice revealed numerous pathological vacuoles within the large
neuronal cell bodies of YG8sR mice, present in 17% of all observed
large cells, indicative of the FRDA-like disease phenotype, whereas
no such vacuoles were present in the Y47R control mice (Fig. 7C).
DISCUSSION
FRDA is a lethal inherited disorder for which there is no effective
therapy. Therefore, there is great interest in developing new tools for
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Fig. 4. Hang-wire and grip strength analysis. (A-C) Hang wire. (A) Analysis of YG8sR revealed impaired neuromuscular strength and lack of coordinated
motor control compared with B6 and Y47R controls when both male and female values were taken together (n=10 mice per genotype). Analysis of (B) males
and (C) females separately (n=5 mice per genotype). (D-F) Grip strength. (D) Analysis of YG8sR mice revealed significantly reduced grip strength compared
with B6 and Y47R controls when both males and females were analysed together (n=10 mice per genotype). Analysis of (E) males and (F) females separately
(n=5 mice per genotype). Values represent mean±s.e.m. **P<0.01 and ***P<0.001. Statistical differences between YG8sR FRDA and B6 control mice are

















FRDA therapeutic testing, including the development of FRDA mouse
models. We have previously generated YG8R and YG22R FRDA
mouse models (Al-Mahdawi et al., 2006; Anjomani Virmouni et al.,
2014) that are based upon human FXN YAC transgenic mice
containing a large FXN genomic transgene with GAA repeat
expansions (Al-Mahdawi et al., 2004) crossed with Fxn-knockout
(KO) mice (Cossée et al., 2000). These FRDA mouse models have
proved useful in studies of FRDA disease mechanisms (Chan et al.,
2013; Hayashi et al., 2014; Sahdeo et al., 2014; Shan et al., 2013),
potential novel FRDA drug therapies (Li et al., 2013; Sandi et al.,
2011; Tomassini et al., 2012) and cell-based therapeutic research
(Jones et al., 2013; Jones et al., 2015). However, both YG8R and
YG22R mice have multiple GAA repeat sequences in the human FXN
transgene, which complicates their use in studying the effects of GAA
repeat expansion disease mechanisms and therapies. Furthermore,
both YG8R and YG22R mice have only moderate reductions in
frataxin expression and a resultant mild progressive FRDA-like
disease phenotype. Therefore, it was considered most beneficial to
develop further human-GAA-repeat-expansion-based FRDA mouse
models. We now report the development and characterisation of a new
FRDA mouse model, designated YG8sR, derived from natural
breeding of YG8R mice. YG8sR mice contain a single GAA repeat
sequence within a single FXN transgene, originally 120 GAA repeat
units in size in the founder mouse but, by selective breeding of further
GAA-repeat-expansion mice, we have now established a colony of
YG8sR mice with 200 GAA repeats.
An important aspect of the YG8sR mice is that they contain a
single pure GAA repeat expansion, as we have determined by DNA
sequencing, and this GAA repeat exhibits typical somatic GAA
repeat instability in brain and cerebellum tissues. This is important
because pure GAA repeat expansions are typically identified in
humans with FRDA and they might be essential for somatic GAA-
repeat-instability-associated disease progression (Montermini et al.,
1997), whereas interrupted GAA repeats might induce repeat
stability and less severe FXN gene silencing effects, resulting in a
milder late-onset FRDA phenotype (McDaniel et al., 2001; Stolle et
al., 2008). Furthermore, interruptions in other trinucleotide-repeat
disease mouse models, such as the BACHD and YAC 128 CAG
repeat Huntington disease (HD) transgenic mice, have prevented the
development of a somatic repeat instability phenotype in these mice
(Pouladi et al., 2012), in contrast to three different HD CAG knock-
in (KI) mouse models that all have pure CAG repeats and exhibit
extensive CAG repeat instability (Ishiguro et al., 2001; Shelbourne
et al., 1999; Wheeler et al., 1999).
Another important aspect of the YG8sR mice is that they express
significantly less FXN mRNA and frataxin protein in tissues
compared with the values previously reported for YG8R and
YG22R mice (Al-Mahdawi et al., 2008; Al-Mahdawi et al., 2006;
Anjomani Virmouni et al., 2014). However, this translates into only
a slightly more severe FRDA-like behavioural, biochemical and
histopathological phenotype for YG8sR mice compared with YG8R
and YG22R mice; the YG8sR disease phenotype remains slowly
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Fig. 5. Glucose- and insulin-tolerance tests. (A-C) Glucose-tolerance test. (A) Glucose concentration was higher in YG8sR compared with B6 and Y47R
controls when both male and female values were taken together (n=10 mice per genotype). (B) Similar results were obtained when male values were
considered alone (n=5 mice per genotype). (C) Analysis of female mice showed no statistically significant difference between the YG8sR FRDA and control
mice (n=5 mice per genotype). (D-F) Insulin-tolerance test. (D) YG8sR showed lower blood glucose level after insulin injection compared with B6 and Y47R
controls when both male and female values were considered. (E) Although the blood glucose concentration was normalised after 50 minutes, YG8sR FRDA
male mice exhibited a more rapid glucose lowering after insulin injection. (F) Female mice showed a greater reduction in blood glucose concentration after
















progressive. Therefore, to assist future FRDA therapeutic preclinical
studies we aim to continue selectively breeding YG8sR mice to
produce ever larger GAA repeat expansions leading to further
reductions in frataxin expression, while other laboratories are also
making efforts to generate similar human FXN BAC transgenic mice
with very large pure GAA repeats. At the same time as measuring
FXN expression levels, we also investigated levels of FAST-1
transcripts in YG8sR tissues compared with those in Y47R controls,
and we identified similar significantly decreased levels of both FXN
and FAST-1 expression in all tissues. This is different to previous in
vitro studies carried out by our lab and others of human and mouse
fibroblasts; in these studies, FRDA cells exhibited increased levels
of FAST-1 expression relative to control cells (De Biase et al., 2009;
Sandi et al., 2014). Therefore, further studies will be required to
determine the role, if any, of FAST-1 expression in relation to FXN
expression and FRDA. Our finding of pathological vacuoles within
the large sensory neuronal cell bodies of the DRG of YG8sR mice
is consistent with the initial report by Simon and colleagues, who
identified such vacuoles within their prion-promoter-driven
conditional frataxin-KO mice (Simon et al., 2004), and also with our
own investigations of YG8R and YG22R mice (Al-Mahdawi et al.,
2006; Sandi et al., 2011; Tomassini et al., 2012). However, such
large vacuoles have not been evident in DRG pathological autopsy
specimens from humans with FRDA, which rather exhibit selective
neuronal cell loss (Koeppen et al., 2009). Therefore, our findings in
FRDA mice could be consistent with an early-stage neuronal cell
pathology that perhaps involves autophagy of damaged
mitochondria (mitophagy) before progressing to more complete
neuronal degeneration.
YG8sR mice represent one of the many different approaches to
establish effective FRDA mouse models, which also include
conditional frataxin-KO models (Martelli et al., 2012; Puccio et al.,
2001; Ristow et al., 2003; Simon et al., 2004; Thierbach et al., 2005)
and GAA-repeat KI and KI/KO (KIKO) models (Coppola et al.,
2006; Miranda et al., 2002). The conditional frataxin-KO models,
which exhibit severe early-onset FRDA-like pathologies, have been
extremely useful for assessing potential FRDA drug therapies acting
on the downstream effects of frataxin deficiency, including
antioxidants and iron chelators (Seznec et al., 2004; Whitnall et al.,
2008), and more recently for FRDA gene therapy (Perdomini et al.,
2014). In contrast, the KIKI and KIKO models, which exhibit GAA-
repeat-induced frataxin deficiency but only a mild FRDA-like
phenotype, have been more useful to investigate epigenetic-based
frataxin-increasing drug therapies, such as histone deacetylase
(HDAC) inhibitors (Rai et al., 2010; Rai et al., 2008). We consider
that our YG8sR mice will also continue to be useful for such
epigenetic-based frataxin-increasing drug studies, as YG8R mice
have previously been for HDAC inhibitor studies (Sandi et al.,
2011), and they might also be useful for other drug-, gene- and cell-
based therapeutic approaches. However, it is our consideration that
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Fig. 6. Frataxin expression levels. (A-C) qRT-PCR analysis of transgenic FXN mRNA using mouse-human specific primers. (A) Analysis of males and
females together. Analysis of (B) males and (C) females separately. Data were normalised to the mean FXN mRNA level of Y47R brain samples taken as
100%. Statistical differences between the YG8sR mutant and B6 controls are indicated by the top bar, whereas the bottom bar indicates the differences
between the YG8sR mutant and Y47R controls. (D-F) Dipstick immunoassay of human frataxin protein. (D) Analysis of males and females together, or (E)
males and (F) females separately. Data were normalised to the mean frataxin level of Y47R samples taken as 100%. Values represent mean±s.e.m. *P<0.05,

















the YG8sR mice could be of greatest use to investigate potential
FRDA therapies that specifically target the human FXN gene
sequence to increase frataxin expression, including DNA- or RNA-
based oligotherapies (Sandi et al., 2013) and TALE-VP64 targeting
of the FXN promoter (Chapdelaine et al., 2013). Owing to potential
gender-specific effects of any particular therapy, we would propose
to study both male and female YG8sR mice in such future
therapeutic studies. In addition, the YG8sR mice will also be very
useful to investigate any future strategies that might emerge to
address the question of somatic GAA repeat instability and FRDA
disease progression. In conclusion, we report a novel single-GAA-
repeat-expansion-based FRDA mouse model that is available for
investigators to work towards a therapy for this devastating disease.
MATERIALS AND METHODS
Transgenic mice, cell culture, DNA extraction and GAA repeat
analysis
A founder YG8sR mouse containing ~120 GAA repeats was obtained by
natural breeding of YG8R mice, and the new YG8sR line has been
maintained on a predominantly C57BL6/J background. These mice are
available from The Jackson Laboratory: YG8sR (#024113). Other mice are
also available from The Jackson Laboratory: Y47R (#024097), YG8R
(#012253) and YG22R (#012910). Mice were housed in conventional open
cages with Litaspen Premium 8/20 bedding, paper wool nesting and standard
fun tunnel environmental enrichment. The animal husbandry was carried out
at 11 hour dark versus 13 hour light, 20-23°C and 45-60% humidity. The
mice were nourished with a diet of SDS RM3 expanded food pellets and
standard drinking water. All procedures were carried out in accordance with
the UK Home Office ‘Animals (Scientific Procedures) Act 1986’ and with
approval from the Brunel University Animals Welfare and Ethical Review
Board. Mouse fibroblast cell lines were established from the kidneys of B6
mice and FXN YAC transgenic mouse models as previously described
(Sandi et al., 2014). Genomic DNA was extracted from the FRDA and
control mouse tissues and fibroblast cells by standard phenol/chloroform
extraction and ethanol precipitation, and GAA PCR amplification was
carried out using GAA-F (5′-GGGATTGGTTGCCAGTGCTTAAAAG -
TTAG-3′) and GAA-R (5′-GATCTAAGGACCATCATGGCCACACT -
TGCC-3′) primers (Campuzano et al., 1996), followed by sizing on agarose
gels, as previously described (Al-Mahdawi et al., 2004). To determine
YG8sR GAA repeat purity, MboII digestion of GAA PCR products and
subsequent agarose gel electrophoresis was carried out as previously
described (Holloway et al., 2011). To sequence the YG8sR GAA repeat,
genomic DNA was extracted from fibroblast cells using the DNeasy Blood
and Tissue kit (Qiagen), PCR amplification was performed on 50 ng of
DNA using Q5 High Fidelity DNA polymerase (NEB) and primers 104F
and 629R as previously described (Bidichandani et al., 1998), and Sanger
sequencing was carried out with primer 629R.
Estimation of transgene copy number
TaqMan copy number assays
The frataxin copy number was determined using TaqMan copy number
assays (Applied Biosystems) according to the manufacturer’s instructions.
In brief, 20 ng of genomic DNA was combined with 2× TaqMan universal
master mix, TaqMan copy number assay for human FXN (Hs05092416_cn
or Hs02407730_cn), and TaqMan copy number reference assay for mouse
Tert in a 20 μl reaction volume. The assay was performed using the 7900-
HT real-time polymerase chain reaction system and the following thermal
cycling conditions: 50°C for 2 minutes, 95°C for 10 minutes, and 40
cycles of 95°C for 15 seconds and 60°C for 1 minute. Samples were
assayed using triplicate wells for each gene of interest and copy numbers
were estimated by relative quantitation (RQ) normalised to the known
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Fig. 7. FAST-1 expression, aconitase activity and DRG pathology. (A) qRT-PCR analysis of FAST-1 expression. Data were normalised to the mean FAST-1
level of Y47R brain samples taken as 100%. Values represent mean±s.e.m. **P<0.01, ***P<0.001. (B) Aconitase activity assays were performed twice on two
samples in triplicate with values being calculated relative to citrate synthase activities. Activity ratios are shown relative to the Y47R mouse cell value taken as
100%. Values represent mean±s.e.m. *P<0.05. (C) H&E staining of DRG sections from Y47R and YG8sR FRDA mice. Arrows show vacuolar degeneration in
















copy number of the reference sequence using the comparative Ct (∆∆Ct)
method. The Ct data were subsequently compared to a calibrator sample
known to have two copies of the target sequence, analysed by Applied
Biosystems CopyCaller Software (v.2.0; Applied Biosystems) according
to the product instruction.
Fluorescence in situ hybridisation assay
Cell cultures were harvested after exposure to colcemid for 4 hours and
chromosome preparations were obtained according to standard cytogenetic
methods. However, for interphase analysis, samples were produced without
colcemid treatment. Cells were spread onto slides and were then denatured
in 70% formamide in 2× SSC at 70°C for 5 minutes. The probes were
prepared using purified DNA from RP11-265B8 and RP11-876N18 BAC
clones, which were labelled by nick translation with biotin and digoxigenin,
respectively, according to the manufacturer’s instructions (Roche). The
labelled DNAs were ethanol precipitated together with Cot-1 human DNA
(Roche) and resuspended in 10 μl of hybridisation buffer (Sigma). The
probes were incubated at 65°C for 10 minutes, followed by preannealing at
37°C for 10 minutes. Hybridisation was carried out at 37°C overnight
followed by washing with 2× SSC for 5 minutes. The RP11-265B8 probe
was detected with Avidin D-Texas Red, biotinylated anti-Avidin D and
Avidin D-Texas Red (Vector Laboratories). The RP11-876N18 was detected
with mouse anti-digoxigenin antibody (Sigma-Aldrich) followed by rabbit
anti-mouse FITC and anti-rabbit FITC (Sigma-Aldrich). The slides were
mounted in VECTASHIELD (Vector Laboratories, Burlingame, CA, USA)
containing DAPI counterstain.
Behavioural testing
Body weight analysis and rotarod test
Weighing and rotarod tests were performed once a month from 4-12 months
of age, using ten mice (five males and five females) from each group (B6,
Y47R and YG8sR). Motor coordination ability was assessed using a Ugo-
Basille 7650 accelerating rotarod treadmill. Four trials were performed with
the speed of the rotation gradually increasing from 4 to 40 rpm and each trial
lasted approximately 3 to 5 minutes, separated by a rest period of 200
seconds between each trial. The time taken for the mouse to fall from the
apparatus was recorded and the maximum time on the rotarod was set at 400
seconds. 
Beam-breaker locomotor activity test
Average velocity, ambulatory distance, vertical counts, vertical time, jump
counts and jump time were measured over a 1-minute period and repeated
five times for each mouse using a beam-breaker activity monitor (MED-
OFA-510 activity chamber; Med Associates). Locomotor activity of the
mice (n=10 including five males and five females used for each group) was
assessed monthly over an 8-month period from 4 to 12 months of age. Data
analysis and manipulation was performed using Microsoft Excel.
Beam-walk test
The beam-walk test was carried out using 90-cm long, 12-mm and 22-mm
diameter, horizontal wooden beams. Coordination ability was assessed by
measuring the time taken for the mouse to cross the beam. Mice received
two trainings and were assessed four times on each beam with a rest period
of 5 minutes between each trial.
Hang wire test
The hang wire test was performed to assess forelimb grip strength. The mice
were hung from a horizontally positioned wire (2 mm in diameter and 30 cm
long) with each end affixed to a vertical stand. Bedding material was placed
underneath the wire to break the fall. The test commenced shortly after the
mouse held onto the wire and the length of time before the fall was recorded.
Four trials were performed with a rest period of 5 minutes between each trial.
Grip strength test
The grip strength meter (Salter Brecknell Model 12 Spring Balance) was
also used to assess the forelimb grip strength. The mice, held by the base of
the tail, were allowed to freely grasp a metal bar attached to a strain meter.
The peak force with which mice pulled the bar horizontally was measured
in four trials with a rest period of 5 minutes between each trial.
Footprint test
To obtain the footprints, mouse paws were dipped in nontoxic water-based
food dye. The mice were allowed to walk along a 40-cm long, 9.5-cm wide,
gangway (with 7-cm-high side walls) with white paper lining the floor. All
mice had one training run and were then given three trials. Three steps from
the middle portion of each run with a total number of nine steps for each
mouse were measured for left hind and front stride length, right hind and
front stride length, fore base width (the width between the right and left
forelimbs) and hind base width (the width between the right and left
hindlimbs).
Glucose- and insulin-tolerance tests
To determine fasting blood glucose levels, 1 mg/g glucose solution (D-
Glucose; Sigma-Aldrich) was injected intraperitoneally into the mice after
a 16-hour fasting period. Blood glucose was measured from the tail vein
immediately prior to glucose administration and after 20, 40 and 60 minutes
with a glucometer (ACCU-CHEK Aviva blood glucose meter; Roche). For
insulin-tolerance testing, the mice were fasted for 16 hours. Blood glucose
was first measured from the tail vein, then the mice received an
intraperitoneal injection of insulin (0.75 U/kg; Sigma-Aldrich) and blood
glucose was measured again at time points of 20, 50 and 80 minutes after
injection.
Quantitative reverse transcriptase PCR
Total RNA was isolated from the mouse tissues by homogenisation with
Trizol (Invitrogen) and cDNA was then prepared by using AMV reverse
transcriptase (Invitrogen) with oligo(dT)20 primers following the
manufacturer’s instructions. Levels of human transgenic FXN or endogenous
Fxn mRNA expression were assessed by qPCR using an ABI Prism 7900HT
Sequence Detection System and SYBR® Green (Applied Biosystems) with
the following primers that equally amplify human and mouse sequences:
FRT-I forward 5′-TTGAAGACCTTGCAGACAAG-3′ and RRT-II reverse
5′-AGCCAGATTTGCTTGTTTGG-3′, 121-bp amplicon size. Mouse
Gapdh RT-PCR primers used for normalisation were as follows: Gapdhm
forward 5′-ACCCAGAAGACTGTGGATGG-3′ and Gapdhm reverse 5′-
GGATGCAGGGATGATGTTCT-3′, 81-bp amplicon size. Assays were
performed in triplicate in at least two independent experiments. FAST-1
expression levels were determined as previously described (Sandi et al.,
2014).
Frataxin dipstick assay
Protein concentration was quantified by BCA assay and the levels of frataxin
protein were measured by lateral flow immunoassay with the Frataxin Protein
Quantity Dipstick Assay Kit (MitoSciences, Eugene, OR, USA) according to
the manufacturer’s instructions (Willis et al., 2008). Signal intensity was
measured with a Hamamatsu ICA-1000 Immunochromatographic Reader
(MitoSciences).
Histology
Histological preparations of mouse DRG were carried out by dissection of
paraformaldehyde-fixed intact lumbar vertebrae, followed by decalcification
treatment in Hillman and Lee’s EDTA daily for 5 days. Tissues were then
embedded in paraffin wax, sectioned by standard methods, deparaffinized
with IMS and Histoclear (National Diagnostics), and slides were stained
with H&E.
Aconitase assay
Aconitase activities were determined using the Aconitase Assay Kit
(Cayman Chemical Company, 705502). Cell protein lysates (50 μl) were
added to 200 μl of substrate mix [50 mM Tris/HCl pH 7.4, 0.4 mM NADP,
5 mM Na citrate, 0.6 mM MgCl2, 0.1% (v/v) Triton X-100 and 1 U
isocitrate dehydrogenase] and the reactions were incubated at 37°C for 15
minutes, followed by spectrophotometric absorbance measurements at 340
nm at 37°C every minute for 15 minutes and subsequent determination of
the reaction slope. Aconitase activities of mouse cells were then normalized
to citrate synthase activities, which were determined using a citrate synthase
assay kit (Sigma, CS0720).
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For statistical analysis, the unpaired two-tailed Student’s t-test or the two-
way analysis of variance (ANOVA) test were used to assess the significance
of the differences between group data with a significance value set at
P<0.05.
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